RT Journal Article
SR Electronic
T1 Post-COVID Syndrome. A Case Series and Comprehensive Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.17.21260655
DO 10.1101/2021.07.17.21260655
A1 Anaya, Juan-Manuel
A1 Rojas, Manuel
A1 Salinas, Martha L.
A1 Rodríguez, Yhojan
A1 Roa, Geraldine
A1 Lozano, Marcela
A1 Rodríguez-Jiménez, Mónica
A1 Montoya, Norma
A1 Zapata, Elizabeth
A1 ,
A1 Monsalve, Diana M
A1 Acosta-Ampudia, Yeny
A1 Ramírez-Santana, Carolina
YR 2021
UL http://medrxiv.org/content/early/2021/07/20/2021.07.17.21260655.abstract
AB The existence of a variety of symptoms with a duration beyond the acute phase of COVID-19, is referred to as post-COVID syndrome (PCS). We aimed to report a series of patients with PCS attending a Post-COVID Unit and offer a comprehensive review on the topic. Adult patients with previously confirmed SARS-CoV-2 infection were systematically assessed through a semi-structured and validated survey. Total IgG, IgA and IgM serum antibodies to SARS-CoV-2 were evaluated by an electrochemiluminescence immunoassay. A systematic review of the literature and meta-analysis were conducted, following PRISMA guidelines. Univariate and multivariate methods were used to analyze data. Out of a total of 100 consecutive patients, 53 were women, the median of age was 49 years (IQR: 37.8 to 55.3), the median of post-COVID time after the first symptoms was 219 days (IQR: 143 to 258), and 65 patients were hospitalized during acute COVID-19. Musculoskeletal, digestive (i.e., diarrhea) and neurological symptoms including depression (by Zung scale) were the most frequent observed in PCS patients. A previous hospitalization was not associated with PCS manifestation. Arthralgia and diarrhea persisted in more than 40% of PCS patients. The median of anti-SARS-CoV-2 antibodies was 866.2 U/mL (IQR: 238.2 to 1681). Despite this variability, 98 patients were seropositive. Based on autonomic symptoms (by COMPASS 31) two clusters were obtained with different clinical characteristics. Levels of anti-SARS-CoV-2 antibodies were not different between clusters. A total of 40 articles (11,196 patients) were included in the meta-analysis. Fatigue/muscle weakness, dyspnea, pain and discomfort, anxiety/depression and impaired concentration were presented in more than 20% of patients reported. In conclusion, PCS is mainly characterized by musculoskeletal, pulmonary, digestive and neurological involvement including depression. PCS is independent of severity of acute illness and humoral response. Long-term antibody responses to SARS-CoV-2 infection and a high inter-individual variability were confirmed. Future studies should evaluate the mechanisms by which SARS-CoV-2 may cause PCS and the best therapeutic options.HighlightsPCS is mainly characterized by musculoskeletal, pulmonary, digestive and neurological involvement including depression.PCS is independent of severity of acute illness and humoral immune response.Autonomic symptoms may help to classify patients with PCS.Long-term antibody responses to SARS-CoV-2 infection and a high inter-individual variability were confirmed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by grants from Universidad del Rosario (ABN011).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was done in compliance with Act 008430/1993 of the Ministry of Health of the Republic of Colombia, which classified it as minimal-risk research. All the patients were asked for their consent and were informed about the Colombian data protection law (1581 of 2012). The institutional review board of the Universidad del Rosario approved the study design.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available prior request to corresponding authorCIConfidence interval.COMPASS 31Composite autonomic symptom score 31.COVID-19Coronavirus disease 2019.DLCODiffusing capacity for carbon monoxide.ECLIAElectrochemiluminescence immunoassay.ELISAEnzyme-linked immunosorbent assay.ICUIntensive care unit.IQRInterquartile range.NANot applicable/available.PCSPost-COVID syndrome.POTSPostural orthostatic tachycardia syndrome.PRISMAPreferred Reporting Items for Systematic Reviews and Meta-analyses.RBDReceptor binding domain.S/CoSignal-to-cut-off.SARS-CoV-2Severe acute respiratory syndrome coronavirus 2.TNFTumor necrosis factor.